DMAC vs DOW · $157.4M cap vs P/E 74, rev $42.96B
DiaMedica Therapeutics Inc (DMAC) versus Dow Inc (DOW) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Dow Inc (DOW) is a chemicals company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported DOW revenue for 2024-12-31 was $42.96B. Net income was $1.20B. Revenue was down 3.7% from 2023-12-31 to 2024-12-31. DOW currently screens at market cap $20.89B and trailing P/E 73.9.
DMAC currently screens at market cap $157.4M. DOW currently screens at market cap $20.89B and trailing P/E 73.9.
Not investment advice. Open the DMAC and DOW stock pages for the full models.
Not investment advice.